Thomas Hitchcock, Ph.D.
이 콘텐츠는 아직 번역되지 않았습니다.
Thomas Hitchcock, Ph.D. is Chief Innovation Officer at Revance. In the Botulinum Index graph, he is the current Revance innovation-leadership node most directly suited to explaining the company’s product-science framing around Daxxify and adjacent aesthetics technologies.
His page complements the commercial and ownership context on Revance / Crown Laboratories. It keeps Daxxify’s peptide-formulated identity connected to product science without turning that formulation difference into an unsupported comparison claim.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Revance |
| Current role | Chief Innovation Officer |
| Company context | Revance within the Crown Laboratories corporate group |
| Relevant company node | Revance / Crown Laboratories |
| Relevant brand node | Daxxify |
| Official leadership source | Revance: Leadership Team and Board of Directors 🔗 |
Career Notes
Section titled “Career Notes”- Revance identifies Hitchcock as Chief Innovation Officer on its current leadership page.
- Revance describes its innovation work across aesthetics, skincare, and therapeutics.
- Revance’s science page describes a peptide-formulated neuromodulator as developed and manufactured by Revance.
- The company’s current portfolio also includes Daxxify safety and indication language for glabellar lines and cervical dystonia in adults.
Innovation and Product-Science Context
Section titled “Innovation and Product-Science Context”Hitchcock is useful because Daxxify is often discussed through its formulation identity. Revance describes Daxxify as a peptide-formulated neuromodulator, and that language helps distinguish the product in the U.S. type A toxin map.
The distinction should remain product-specific. It does not make Daxxify units interchangeable with other botulinum toxin products, and it should not be used as a generalized claim that Daxxify is safer, stronger, longer-lasting, or clinically superior across patients or indications.
Activity and Public Context
Section titled “Activity and Public Context”Revance’s current science materials frame innovation around product development, formulation sciences, R&D, clinical studies, medical affairs, and sponsored-trial support. Hitchcock’s leadership role belongs in that context: he helps anchor the scientific and innovation side of the current Revance node rather than the historical CEO period around Daxxify’s original approval.
For readers following the graph, Hitchcock pairs naturally with Darin J. Messina, Ph.D. as an R&D and product-science counterpart outside AbbVie / Allergan Aesthetics.